In re: Merck Mumps Vaccine Antitrust Litigation

23-3089

January 16, 2025
Merck Defends 3rd Circ. Win In Mumps Vaccine Antitrust Case

Merck urged the Third Circuit not to reconsider a ruling that immunized the company from antitrust claims over submissions it made to federal regulators for its mumps vaccine, arguing the appeals court was right to find the submissions were protected.
November 27, 2024
Nonprofit Warns 3rd Circ. Against 'Abuse' In Merck Vax Case

The anti-monopoly think tank Open Markets Institute urged the full Third Circuit to rethink a panel's immunization of Merck & Co. Inc. from antitrust claims over its mumps vaccine, arguing in an amicus brief that the doctrine cementing the right to petition the government doesn't justify the use of courts and administration as a "competitive weapon."
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says

A divided Third Circuit panel inoculated Merck from claims that it tried to prevent competition by making inflated declarations to federal regulators about its mumps vaccine, with the majority ruling Monday that because Merck convinced federal regulators it had extended the vaccine's long-term potency, those assertions can't have been an anticompetitive "sham."